Cargando…
DIPG-03. THERAPEUTIC TARGETING OF TRANSCRIPTIONAL ELONGATION IN DIFFUSE INTRINSIC PONTINE GLIOMA
Diffuse intrinsic pontine glioma (DIPG) is highly aggressive brain stem tumor and needed to develop novel therapeutic agents for the treatment. The super elongation complex (SEC) is essential for transcription elongation through release of RNA polymerase II (Pol II). We found that AFF4, a scaffold p...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7715649/ http://dx.doi.org/10.1093/neuonc/noaa222.055 |
_version_ | 1783619004970041344 |
---|---|
author | Katagi, Hiroaki Takata, Nozomu Aoi, Yuki Zhang, Yongzhan Rendleman, Emily J Blyth, Gavin T Eckerdt, Frank D Tomita, Yusuke Sasaki, Takahiro Saratsis, Amanda M Kondo, Akihide Goldman, Stewart Becher, Oren J Smith, Edwin Zou, Lihua Shilatifard, Ali Hashizume, Rintaro |
author_facet | Katagi, Hiroaki Takata, Nozomu Aoi, Yuki Zhang, Yongzhan Rendleman, Emily J Blyth, Gavin T Eckerdt, Frank D Tomita, Yusuke Sasaki, Takahiro Saratsis, Amanda M Kondo, Akihide Goldman, Stewart Becher, Oren J Smith, Edwin Zou, Lihua Shilatifard, Ali Hashizume, Rintaro |
author_sort | Katagi, Hiroaki |
collection | PubMed |
description | Diffuse intrinsic pontine glioma (DIPG) is highly aggressive brain stem tumor and needed to develop novel therapeutic agents for the treatment. The super elongation complex (SEC) is essential for transcription elongation through release of RNA polymerase II (Pol II). We found that AFF4, a scaffold protein of the SEC, is required for the growth of H3K27M-mutant DIPG cells. In addition, the small molecule SEC inhibitor, KL-1, increased promoter-proximal pausing of Pol II, and reduced transcription elongation, resulting in down-regulate cell cycle, transcription and DNA repair genes. KL-1 treatment decreased cell growth and increased apoptosis in H3K27M-mutant DIPG cells, and prolonged animal survival in our human H3K27M-mutant DIPG xenograft model. Our results demonstrate that the SEC disruption by KL-1 is a novel therapeutic strategy for H3K27M-mutant DIPG. |
format | Online Article Text |
id | pubmed-7715649 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-77156492020-12-09 DIPG-03. THERAPEUTIC TARGETING OF TRANSCRIPTIONAL ELONGATION IN DIFFUSE INTRINSIC PONTINE GLIOMA Katagi, Hiroaki Takata, Nozomu Aoi, Yuki Zhang, Yongzhan Rendleman, Emily J Blyth, Gavin T Eckerdt, Frank D Tomita, Yusuke Sasaki, Takahiro Saratsis, Amanda M Kondo, Akihide Goldman, Stewart Becher, Oren J Smith, Edwin Zou, Lihua Shilatifard, Ali Hashizume, Rintaro Neuro Oncol Diffuse Midline Glioma/DIPG Diffuse intrinsic pontine glioma (DIPG) is highly aggressive brain stem tumor and needed to develop novel therapeutic agents for the treatment. The super elongation complex (SEC) is essential for transcription elongation through release of RNA polymerase II (Pol II). We found that AFF4, a scaffold protein of the SEC, is required for the growth of H3K27M-mutant DIPG cells. In addition, the small molecule SEC inhibitor, KL-1, increased promoter-proximal pausing of Pol II, and reduced transcription elongation, resulting in down-regulate cell cycle, transcription and DNA repair genes. KL-1 treatment decreased cell growth and increased apoptosis in H3K27M-mutant DIPG cells, and prolonged animal survival in our human H3K27M-mutant DIPG xenograft model. Our results demonstrate that the SEC disruption by KL-1 is a novel therapeutic strategy for H3K27M-mutant DIPG. Oxford University Press 2020-12-04 /pmc/articles/PMC7715649/ http://dx.doi.org/10.1093/neuonc/noaa222.055 Text en © The Author(s) 2020. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Diffuse Midline Glioma/DIPG Katagi, Hiroaki Takata, Nozomu Aoi, Yuki Zhang, Yongzhan Rendleman, Emily J Blyth, Gavin T Eckerdt, Frank D Tomita, Yusuke Sasaki, Takahiro Saratsis, Amanda M Kondo, Akihide Goldman, Stewart Becher, Oren J Smith, Edwin Zou, Lihua Shilatifard, Ali Hashizume, Rintaro DIPG-03. THERAPEUTIC TARGETING OF TRANSCRIPTIONAL ELONGATION IN DIFFUSE INTRINSIC PONTINE GLIOMA |
title | DIPG-03. THERAPEUTIC TARGETING OF TRANSCRIPTIONAL ELONGATION IN DIFFUSE INTRINSIC PONTINE GLIOMA |
title_full | DIPG-03. THERAPEUTIC TARGETING OF TRANSCRIPTIONAL ELONGATION IN DIFFUSE INTRINSIC PONTINE GLIOMA |
title_fullStr | DIPG-03. THERAPEUTIC TARGETING OF TRANSCRIPTIONAL ELONGATION IN DIFFUSE INTRINSIC PONTINE GLIOMA |
title_full_unstemmed | DIPG-03. THERAPEUTIC TARGETING OF TRANSCRIPTIONAL ELONGATION IN DIFFUSE INTRINSIC PONTINE GLIOMA |
title_short | DIPG-03. THERAPEUTIC TARGETING OF TRANSCRIPTIONAL ELONGATION IN DIFFUSE INTRINSIC PONTINE GLIOMA |
title_sort | dipg-03. therapeutic targeting of transcriptional elongation in diffuse intrinsic pontine glioma |
topic | Diffuse Midline Glioma/DIPG |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7715649/ http://dx.doi.org/10.1093/neuonc/noaa222.055 |
work_keys_str_mv | AT katagihiroaki dipg03therapeutictargetingoftranscriptionalelongationindiffuseintrinsicpontineglioma AT takatanozomu dipg03therapeutictargetingoftranscriptionalelongationindiffuseintrinsicpontineglioma AT aoiyuki dipg03therapeutictargetingoftranscriptionalelongationindiffuseintrinsicpontineglioma AT zhangyongzhan dipg03therapeutictargetingoftranscriptionalelongationindiffuseintrinsicpontineglioma AT rendlemanemilyj dipg03therapeutictargetingoftranscriptionalelongationindiffuseintrinsicpontineglioma AT blythgavint dipg03therapeutictargetingoftranscriptionalelongationindiffuseintrinsicpontineglioma AT eckerdtfrankd dipg03therapeutictargetingoftranscriptionalelongationindiffuseintrinsicpontineglioma AT tomitayusuke dipg03therapeutictargetingoftranscriptionalelongationindiffuseintrinsicpontineglioma AT sasakitakahiro dipg03therapeutictargetingoftranscriptionalelongationindiffuseintrinsicpontineglioma AT saratsisamandam dipg03therapeutictargetingoftranscriptionalelongationindiffuseintrinsicpontineglioma AT kondoakihide dipg03therapeutictargetingoftranscriptionalelongationindiffuseintrinsicpontineglioma AT goldmanstewart dipg03therapeutictargetingoftranscriptionalelongationindiffuseintrinsicpontineglioma AT becherorenj dipg03therapeutictargetingoftranscriptionalelongationindiffuseintrinsicpontineglioma AT smithedwin dipg03therapeutictargetingoftranscriptionalelongationindiffuseintrinsicpontineglioma AT zoulihua dipg03therapeutictargetingoftranscriptionalelongationindiffuseintrinsicpontineglioma AT shilatifardali dipg03therapeutictargetingoftranscriptionalelongationindiffuseintrinsicpontineglioma AT hashizumerintaro dipg03therapeutictargetingoftranscriptionalelongationindiffuseintrinsicpontineglioma |